Ontology highlight
ABSTRACT:
SUBMITTER: Jena B
PROVIDER: S-EPMC3995024 | biostudies-literature | 2014 Mar
REPOSITORIES: biostudies-literature
Jena Bipulendu B Moyes Judy S JS Huls Helen H Cooper Laurence J N LJ
Current hematologic malignancy reports 20140301 1
T cells that have been genetically modified, activated, and propagated ex vivo can be infused to control tumor progression in patients who are refractory to conventional treatments. Early-phase clinical trials demonstrate that the tumor-associated antigen (TAA) CD19 can be therapeutically engaged through the enforced expression of a chimeric antigen receptor (CAR) on clinical-grade T cells. Advances in vector design, the architecture of the CAR molecule especially as associated with T-cell co-st ...[more]